Key result
Angiotensin II increases insulin sensitivity ~29% and muscle blood flow vs placebo, antagonized by irbesartan.
Why the study?
It is unclear whether the effects of angiotensin II on insulin sensitivity and skeletal muscle blood flow are mediated via subtype 1 receptors of angiotensin II.
Does Angiotensin II infusion alter muscle and renal blood flow and insulin sensitivity in healthy subjects, and are these effects mediated by AT1 receptors?
RCT (n=9)
Double-blind
random order
Does Angiotensin II infusion alter muscle and renal blood flow and insulin sensitivity in healthy subjects, and are these effects mediated by AT1 receptors?
Under hyperinsulinemic euglycemic conditions, Angiotensin II causes AT1-receptor-mediated vasodilation in skeletal muscle but vasoconstriction in renal vasculature.
Answers are grounded in this paper and cite their sources.
Ang II may enhance insulin sensitivity via AT1-mediated muscle vasodilation in healthy subjects; extends mechanistic insights into differential vascular effects.
We have previously demonstrated that Ang II enhances insulin sensitivity in humans and this is associated with a paradoxical increase in skeletal muscle blood flow. It is unclear whether these effects are mediated via subtype 1 receptors of Ang II, since these receptors are thougth to mediate vasoconstriction. We measured insulin-stimulated glucose uptake (euglycemic clamp) and leg muscle blood flow (plethysmography) in 9 healthy subjects (mean age 24 ± 2 y) on three occasions using a double blind placebo controlled study design. The subjects were allocated in random order to: (i) placebo premedication per os plus placebo infusion, (ii) placebo per os plus infusion of 5 ng Ang II/kg/min, and (iii) premedication with 300 mg of the angiotensin II-1-receptor antagonist irbesartan per os plus infusion of 5 ng Ang II/kg/min. In addition, GFR and effective renal plasma flow were assessed (inulin- and PAH-clearance). Insulin sensitivity (i.e. M-value) and muscle blood flow after infusion of Ang II (9.3 ± 1.8 mg/kg/min; 17.7 ± 2.2 ml/100g/min) were significantly higher (p < 0.05) than after placebo infusion (7.2 ± 1.6; 13.5 ± 1.8). In contrast, after irbesartan premedication they were not significantly different (7.5 ± 1.7; 14.3 ± 1.9) as compared with placebo infusion. Mean GFR and effective renal plasma flow were significantly lower (p < 0.05) and renal vascular resistance higher (p < 0.05) with Ang II infusion (107 ± 6 ml/min/1.73 m2; 461 ± 44 ml/min/1.73 m2; 126 ± 15 mmHg/ml/min) as compared with placebo infusion (120 ± 6; 672 ± 51; 74 ± 6). Irbesartan almost completely blocked the vasoconstrictive effect of Ang II on renal vasculature (118 ± 6; 650 ± 36; 76 ± 6). We conclude that under hyperinsulinemic euglycemic conditions Ang II has opposing effects on regional arterial blood flow, i.e. vasodilation in skeletal muscles but vasoconstriction of renal vasculature. Both effects are antagonized by blockade of subtype 1 Ang II receptors.
No takes yet. Share an insight, caveat, or question.
Danilo Fliser (2000) conducted an RCT in Healthy (n=9). Angiotensin II vs. Placebo was evaluated on Insulin sensitivity (M-value, mg/kg/min) (p=< 0.05). Angiotensin II infusion increased insulin sensitivity and muscle blood flow compared to placebo, effects that were antagonized by irbesartan.
Synapse has enriched 10 related papers. Consider them for comparative context: